期刊文献+

螺旋CT分析胃间质瘤的转移特征与疗效的关系

Spiral CT Analysis for Relationship between Metastic Characteristics and Therapeutic Effect of Gastric Stromal Tumors with Metastasis
原文传递
导出
摘要 目的探讨螺旋CT分析胃间质瘤(gastric stromal tumors,GST)的转移特征和疗效的关系。资料与方法搜集资料完整的GST转移患者22例,回顾性分析和总结该病的转移特征,并评价伊马替尼治疗效果。结果22例GST转移患者中,肝转移13例,脾转移6例;腹壁切口区软组织转移及腹膜、胸膜转移3例;腹膜及盆腔转移4例;淋巴结转移2例;3例CT示有淋巴结肿大,病理证实为轻度反应性增生或轻度慢性炎症改变。伊马替尼治疗11例,多因素分析表明伊马替尼治疗为影响转移性GST患者生存时间的重要因素。结论GST淋巴结转移少见,主要以血行转移为主,并有一定的种植转移概率,伊马替尼近期疗效满意。 Objective To evaluate the value of spiral CT in analyzing metastic characteristics and therapeutic effect of gastric stromal tumors(GST) with metastasis.Materials and Methods A completely clinic history data of 22 patients with metastic GST were collected,metastic features were retrospectively analyzed,and the therapeutic effect of imatinib was evaluated.Results Of the metastic 22 GST,hepatic metastasis in 13,splenic metastasis in 6;soft tissue metastasis around the incision of anterior abdominal wall and pleural metastasis in 3,cavitas pelvis metastasis in 4,lymph node metastasis in 2,pathological results of chronic inflammation or reactive hyperplasia had been confirmed in CT findings of the 3 cases with lymphadenectasis.11 cases were treated with imatinib,Multivariate analysis showed that the administration of imatinib was an important factor on prolonging GST with metastasis.Conclusion GST rarely metastasize to lymph nodes,but can metastasize through blood stream,and sometimes metastasize to regional organs by planting,the near curative effect with imatinib is satisfaction.
出处 《临床放射学杂志》 CSCD 北大核心 2009年第10期1416-1418,共3页 Journal of Clinical Radiology
基金 河南省杰出青年计划项目(编号:084100510020)
关键词 间质瘤 肿瘤转移 体层摄影术 X线计算机 Stomach Stromal tumors Neoplasm metastasis Tomography X-ray computed
  • 相关文献

参考文献11

  • 1Clary BM, DeMatteo RP, Lewis JJ, et al. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitontoneum : a clinical comparison. Ann Surg Oncol,2001,8 :290.
  • 2Rossi ER, Mocellin S, Mencaell R, et al. Gastrointestinal stromal tumors from a surgical to a molecular approach. Int J Cancer,2003, 107 : 171.
  • 3Pierie JP, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg, 2001,136:383.
  • 4Berman J, O' Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol,2001,32 :578.
  • 5吴斌,邱辉忠,关竞红,林国乐,赵玉沛.胃间质瘤70例临床诊治分析[J].中国肿瘤临床,2004,31(16):934-936. 被引量:12
  • 6Hirota S, Isozaki K, Moryama Y, et al. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science, 1998,279: 577.
  • 7Heinrich MC, Corless CL,Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science ,2003,299:708.
  • 8DeMatteo RP, Lewis J J, Leung D, et al. Two hundred gastrointestinal stromal tumors recurrence patterns and prognostic factors for survival. Ann Surg,2000,231:51.
  • 9Carter TA,Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL,KIT,and EGF receptor kinases. Proc Nutl Acad Sci USA,2005,102:11011.
  • 10Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral nmltitarget tyrosine kinase inhibitor,in patients with cancer. J Clin oncul,2006,24:25.

二级参考文献10

  • 1[1]Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology[J].Hum Pathol, 1999, 30(10): 1213~1220
  • 2[2]Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J]. Science,1998, 279(5350): 577~580
  • 3[3]Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointe-stinal stromal tumours [J]. Lancet Onc, 2002, 3(11): 655~664
  • 4[4]Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (ST1571) [J]. Euro J Cancer,2002, 38(sup5): 52~59
  • 5[5]Kim CJ, Day S, Yeh K. Gastrointestinal stromal tumors: analysis of clinical and pathologic factors[J]. Am Surg, 2001, 67(2): 135~138
  • 6[6]DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival[J]. Ann Surg, 2000, 231(1): 51~58
  • 7[7]Matthews BD, Walsh RM, Kercher KW, et al. Laparoscopic vs open resection of gastric stromal tumors[J]. Surg Endosc, 2002, 16(5): 803~807
  • 8[8]Demetri GD, Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].N EnglJ Med, 2002, 347(7): 472~480
  • 9[9]Tmpiano JK, Stewart RE, Misick C, et al. Gastric stromal tumors:A clinicopatho- logic study of 77 cases with nonaggressive and aggressive clinical behaviors [J]. Am J Surg Path, 2002, 26 (6):705~ 714
  • 10[10]Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease[J]. EuroJ Cancer, 2002, 38(sup5): s37~s38

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部